Retrospective analysis of the results of whole-body PET/CT as a possible tool for clinical examination of the population in order to identify subclinical manifestations of chronic kidney disease (pilot study)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Every year in Russia, more than 200 thousand whole body PET/CT are performed for various diseases in patients without clinical and laboratory manifestations of chronic kidney disease (CKD). However, only the “area of interest” of the attending physician is analyzed, while the rest of the organs or rather their metabolic activity is neglected during the standard procedure of this contemporary and high-tech research method. Aim. To perform a retrospective study of whole-body PET/CT as a tool for prophylactic clinical examination of the population in order to identify subclinical manifestations of chronic kidney disease Materials and methods: The results of whole-body PET/CT with 11C-choline were retrospectively analyzed for the detection of CKD in 100 patients of the Tyumen region who underwent a study for various indications outside the genitourinary system without history, clinical and laboratory manifestations of CKD. Results: According to the results, 22% of patients had different manifestations of 11C-choline hypometabolism, indicating a decrease in the viability of the parenchyma. In 14% of patients, there was a local decrease in the uptake of 11C-choline without CT-signs of kidneys damage, and in 8% of cases there was a total decrease in their metabolism, coinciding with X-ray signs of renal scarring. Conclusions. The possibility of early molecular study of nephropathy can be used for wider retrospective PET/CT clinical examination as one of the highly effective methods for detecting CKD, which needs further research.

全文:

受限制的访问

作者简介

B. Berdichevsky

FGBOU VO "Tyumen State Medical University" of the Ministry of Health of Russia

Ph.D., MD, professor at the Department of Oncology with a course of Urology Tyumen, Russia

V. Berdichevsky

FGBOU VO "Tyumen State Medical University" of the Ministry of Health of Russia

Email: neurourofcn@mail.ru
Ph.D., MD, associate professor at the Department of Oncology with a course of Urology Tyumen, Russia

E. Sapozhenkova

FGBOU VO "Tyumen State Medical University" of the Ministry of Health of Russia

Department of Oncology with the course of urology; Ph.D., associate professor at the Department of Normal Physiology Tyumen, Russia

A. Romanova

FGBOU VO "Tyumen State Medical University" of the Ministry of Health of Russia

Ph.D. student at the Department of Oncology with a course of Urology Tyumen, Russia

F. Rasulov

FGBOU VO "Tyumen State Medical University" of the Ministry of Health of Russia

Ph.D. student at the Department of Oncology with a course of Urology Tyumen, Russia

M. Korabelnikov

FGBOU VO "Tyumen State Medical University" of the Ministry of Health of Russia; GAUZ TO MK MC “Mecial City”

Department of Oncology with the course of urology; radiologist at the Center of Radiology Tyumen, Russia

参考

  1. Daisuke Katagiri, Shoichi Masumoto, Ai Katsuma, Eri Minami. Positron emission tomography combined with computed tomography (PET-CT) as a new diagnostic tool for acute tubulointerstitial nephritis (AIN) in oliguric or haemodialysed patients. NDT Plus. 2010;3(2):155-159.
  2. Christopher C. Riedl, Elina Slobod, Maxine Jochelson. Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years J Nucl Med. 2014;55(10):1578-1583. doi: 10.2967/jnumed.114.143297.
  3. Kamyar Kalantar-Zadeh, Tazeen H Jafar, Dorothea Nitsch, Brendon L Neuen, Vlado Perkovic. Chronic kidney disease. The Lancet. Published: June 24,2021. Doi: https://doi.org/10.1016/S0140-6736(21)00519-5
  4. Scott Wilson B.A., Pasquale Mone, Stanislavas S. Author information Copyright and License information Disclaimer Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk J Clin Hypertens (Greenwich). 2021;23(4):831-834.
  5. Chu C.D., McCulloch C.E., Banerjee T., et al. Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. CKD awareness among US adults by future risk of kidney failure. Am J Kidney Dis. 2020;76(2):174-1803.
  6. Satyanarayana R. Vaidya, Narothama R. Aeddula. Chronic Renal Failure In: StatPearls Publishing; 2021 Jan. PMID: 30571025 Bookshelf ID: NBK535404
  7. Nakajima R., Nozaki S., Kondo T., Nagashima Y., Abe K., Sakai S. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. European radiology 2017;27(11):4866-4873.
  8. Badawi R.D., Shi H., Hu P., Chen S., Xu T., Price P.M. et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60(3):299-303. doi: 10.2967/jnumed.119.226498.
  9. Kwee C., Andor W.J. Glaudemans, Limitations, Pitfalls of FDG-PET/ CT in Infection and Inflammation Seminars in Nuclear Medicine. 2021;51(6):633-645.
  10. Alyssa Splan, MaKenna Borofka, Kevin Casper 11C-Choline PET for Evaluation of Renal Tubular Function Journal of Nuclear Medicine May 2018;59(Suppl.):2147.
  11. Van Oostenbrugge, Tim; Mulders. Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab. Current Opinion in Urology. 2021 ;31(3):249-254. doi: 10.1097/MOU.0000000000000872.
  12. Berdichevsky V.B., Berdichevsky B.A.Combinet positron emission and comuted tomography in study of the metabolism of chronic nephrouropati diseases.International Journal of Radiology and Radiation Therapy. 2018;5(5):293-294. doi: 10.15406/ijrrt.2018.05.00181.
  13. Berdichevsky V.B., Berdichevsky B.A et al.Integrative Approach to Assessing the Results of PET/CT of the Human Body. Medical Research and Clinical Case Reports 2.5. 2019;298-300. ISSN: 2578-3416.
  14. Claire Anne Fynbo, Jam Theil, Jesper Nargaard Bech. Estimation of renal perfusion based on measurement of rubidium-82 clearance by PET/CT scanning in healthy subjects EJNMMI Physics. 2021;8:43.
  15. Barbara M. Klinkhammer, Twan Lammers, Felix M. Mottaghy, Fabian Kiessling, Jürgen Floege, Peter Boor. Non-invasive molecular imaging of kidney diseases. Nature Reviews Nephrology. 2021;17:688-703. https://doi.org/10.1038/s41581-021-00440-4
  16. Wan C.H., Tseng J.R., Lee M.H., Yang L.Y., Yen T.C. Clinical utility of FDG PET/CT in acute complicated pyelonephritis-results from an observational study. Eur. J. Nucl. Med. Mol. Imaging. 2018;45:462-470.
  17. Pijl J.P., Glaudemans A., Slart R., Kwee T.C. 18)F-FDG PET/CT in autosomal dominant polycystic kidney disease patients with suspected cyst infection. J. Nucl. Med. 2018;59:1734-1741.
  18. Tseng J.R. et al. Clinical usefulness of 18F-FDG PET/CT for the detection of infections of unknown origin in patients undergoing maintenance hemodialysis. J. Nucl. Med. 2015;56:681-687.
  19. Lovinfosse P. et al. Fluorodeoxyglucose F18 positron emission tomography coupled with computed tomography in suspected acute renal allograft rejection. Am. J. Transpl. 2016;16:310-316.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2022
##common.cookie##